MA33739B1 - Procédés et compositions pour traiter des tumeurs solides et d'autres malignités - Google Patents

Procédés et compositions pour traiter des tumeurs solides et d'autres malignités

Info

Publication number
MA33739B1
MA33739B1 MA34856A MA34856A MA33739B1 MA 33739 B1 MA33739 B1 MA 33739B1 MA 34856 A MA34856 A MA 34856A MA 34856 A MA34856 A MA 34856A MA 33739 B1 MA33739 B1 MA 33739B1
Authority
MA
Morocco
Prior art keywords
malignancies
compositions
methods
solid tumors
treating solid
Prior art date
Application number
MA34856A
Other languages
Arabic (ar)
English (en)
Inventor
Silvia Buonamici
Marion Dorsch
Carlos Garcia-Echeverria
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43384585&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA33739(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA33739B1 publication Critical patent/MA33739B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne une combinaison d'inhibiteurs de kinase mTOR et d'effecteur en aval et d'un inhibiteur de voie hedgehog pour le traitement du cancer.
MA34856A 2009-11-18 2012-05-11 Procédés et compositions pour traiter des tumeurs solides et d'autres malignités MA33739B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26234209P 2009-11-18 2009-11-18
US29203210P 2010-01-04 2010-01-04
PCT/US2010/056942 WO2011062939A1 (fr) 2009-11-18 2010-11-17 Procédés et compositions pour traiter des tumeurs solides et d'autres malignités

Publications (1)

Publication Number Publication Date
MA33739B1 true MA33739B1 (fr) 2012-11-01

Family

ID=43384585

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34856A MA33739B1 (fr) 2009-11-18 2012-05-11 Procédés et compositions pour traiter des tumeurs solides et d'autres malignités

Country Status (18)

Country Link
US (2) US20120232087A1 (fr)
EP (1) EP2501370A1 (fr)
JP (1) JP2013511526A (fr)
KR (1) KR20120107962A (fr)
CN (2) CN102665700A (fr)
AU (1) AU2010322114B2 (fr)
BR (1) BR112012011823A2 (fr)
CA (1) CA2781210A1 (fr)
CL (1) CL2012001271A1 (fr)
IL (1) IL219636A0 (fr)
MA (1) MA33739B1 (fr)
MX (1) MX2012005695A (fr)
NZ (1) NZ599964A (fr)
PH (1) PH12012500911A1 (fr)
RU (1) RU2012125152A (fr)
TN (1) TN2012000205A1 (fr)
WO (1) WO2011062939A1 (fr)
ZA (1) ZA201203325B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2627911T3 (es) 2009-11-18 2017-08-01 Plexxikon, Inc. Derivados de N-[2-fluoro-3-(4-amino-7H-pirrolo[2,3-d]pirimidin-5-carbonil)-fenil]-4-bencenosulfonamida como moduladores de la proteína quinasa Raf para el tratamiento del cáncer
SG194800A1 (en) * 2011-06-02 2013-12-30 Novartis Ag Biomarkers for hedgehog inhibitor therapy
WO2013106812A1 (fr) * 2012-01-12 2013-07-18 Board Of Regents, The University Of Texas System Médicament personnalisé pour la prédiction de thérapie ciblant la voie hedgehog
EP2914253B1 (fr) 2012-11-05 2018-01-03 NantBioScience, Inc. Dérivés contenant un sulfonamide cyclique en tant qu'inhibiteurs de la voie de signalisation hedgehog
CN103524535B (zh) * 2013-10-16 2016-07-13 苏州云轩医药科技有限公司 具有刺猬通路拮抗剂活性的胺基噻唑-吡啶杂环化合物
EP3565520B1 (fr) 2017-01-06 2026-02-25 Palvella Therapeutics, Inc. Compositions anhydres d'inhibiteurs de mtor et méthodes d'utilisation
DK3786160T3 (da) 2017-10-27 2022-08-22 Boehringer Ingelheim Int Pyridinderivater og terapeutiske anvendelser deraf som trpc6-inhibitorer
US11000513B2 (en) 2018-07-02 2021-05-11 Palvella Therapeutics, Inc. Anhydrous compositions of mTOR inhibitors and methods of use
US20210346385A1 (en) * 2018-09-21 2021-11-11 MSB Holdings, Inc Taste-masked dosage forms

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
JP5161102B2 (ja) 2005-11-22 2013-03-13 クドス ファーマシューティカルズ リミテッド ｍＴＯＲ阻害剤としてのピリドピリミジン、ピラゾピリミジンおよびピリミドピリミジン誘導体
UA93548C2 (uk) 2006-05-05 2011-02-25 Айерем Елелсі Сполуки та композиції як модулятори хеджхогівського сигнального шляху
CA2659851C (fr) 2006-08-23 2014-02-25 Kudos Pharmaceuticals Limited Derives de la 2-methylmorpholine pyrido-, pyrazo- et pyrimido-pyrimidine en tant qu'inhibiteurs de mtor
CA2681162C (fr) * 2007-03-15 2015-11-24 Novartis Ag Derives de benzyle et de pyridine comme modulateurs de voie de hedgehog
BR122021010386B1 (pt) * 2007-06-07 2021-08-03 Sun Pharma Global Fze Uso de n-(6-((2r,6s)-2,6-dimetilmorfolino)piridin-3-il)-2-metil-4'-(trifluorometoxi) bifenil-3- carboxamida como moduladores da rota de hedgehog
US8153633B2 (en) * 2007-06-25 2012-04-10 Amgen Inc. Phthalazine compounds, compositions and methods of use
WO2009112266A1 (fr) * 2008-03-12 2009-09-17 Ludwig-Maximilians-Universität Combinaison de principes actifs avec la gemcitabine pour le traitement d'un cancer épithélial
UA102250C2 (ru) * 2008-04-29 2013-06-25 Эли Лилли Энд Компани Двухзамещенные фталазины - антагонисты проводящего пути hedgehog
US20100041663A1 (en) * 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors

Also Published As

Publication number Publication date
US20150025074A1 (en) 2015-01-22
NZ599964A (en) 2014-08-29
AU2010322114A1 (en) 2012-05-31
IL219636A0 (en) 2012-07-31
CL2012001271A1 (es) 2012-10-12
RU2012125152A (ru) 2013-12-27
AU2010322114B2 (en) 2014-07-31
CN104224791A (zh) 2014-12-24
BR112012011823A2 (pt) 2019-09-24
EP2501370A1 (fr) 2012-09-26
PH12012500911A1 (en) 2012-11-26
CN102665700A (zh) 2012-09-12
KR20120107962A (ko) 2012-10-04
ZA201203325B (en) 2013-01-30
US20120232087A1 (en) 2012-09-13
JP2013511526A (ja) 2013-04-04
MX2012005695A (es) 2012-06-13
CA2781210A1 (fr) 2011-05-26
TN2012000205A1 (en) 2013-12-12
WO2011062939A1 (fr) 2011-05-26

Similar Documents

Publication Publication Date Title
MA33739B1 (fr) Procédés et compositions pour traiter des tumeurs solides et d'autres malignités
EP2307025A4 (fr) Inhibiteurs de tyrosine kinase de bruton pour le traitement de tumeurs solides
ATE530540T1 (de) Pyrimidonverbindungen als gsk-3-inhibitoren
MA33909B1 (fr) Pyrrolidinones accoles en tant d'inhibiteurs de syk
GEP20125368B (en) Kinase inhibitors
EA201291099A1 (ru) Новые иммуномодуляторные и противовоспалительные соединения
EP2313091A4 (fr) Compositions pharmaceutiques contenant des inhibiteurs de ret et procédés de traitement du cancer
EA201290184A1 (ru) Бензодиазепиновый ингибитор бромодомена
UA108369C2 (uk) Піролопіримідини як інгібітори cdk4/6
EP2300041A4 (fr) Compositions et procédés pour le traitement ou la prévention du cancer de la prostate et pour la détection de variantes des récepteurs d'androgènes
EA200900613A1 (ru) Спирокетоновые ингибиторы ацетил-коа-карбоксилаз
MA35210B1 (fr) Polythérapie comportant un inhibiteur de cdk4/6 et un inhibiteur de pi3k à utiliser dans le traitement du cancer
EP3313382A4 (fr) Procédés de traitement des tumeurs solides utilisant un traitement combiné contenant des nanoparticules d'inhibiteur de mtor
ATE497496T1 (de) 2,4-pyridimediamon-derivate als hemmer von jak- kinasen zur behandlung von autoimmunerkrankungen
MA33803B1 (fr) Inhibiteur de bromodomaine de benzodiazépine
EP2276509A4 (fr) Détection et traitement du cancer du pancréas, des ovaires et d'autres cancers
EA200970486A1 (ru) Соединения для ингибирования митоза
EA027213B9 (ru) Соединения пиразолопиримидина в качестве ингибиторов киназ
EA200970542A1 (ru) ИНГИБИТОРЫ ДЕЙСТВИЯ Akt
EA201101583A1 (ru) Ингибиторы pi3 киназы или mtor
EA201170531A1 (ru) Соединения на основе пиридина и пиримидина в качестве ингибиторов сигнального пути wnt для лечения рака
EA201270184A1 (ru) Лечение расстройств печени ингибиторами pi3k
EP2182804A4 (fr) Procédés de traitement d'une dépendance
IN2014KN00769A (fr)
EA201200323A1 (ru) Соединения и композиции, как ингибиторы протеинкиназы